Conference Coverage

Osteoprotegerin ups risk of vascular events in type 1 diabetes

Publish date: July 22, 2013

 

AT THE ANNUAL ADA SCIENTIFIC SESSIONS

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Cuba's economic crisis yielded reduced diabetes, CVD, death
Type 2 Diabetes ICYMI
DEA scheduling brings weight-loss drug closer to market
Type 2 Diabetes ICYMI
Gastric bypass helps poorly controlled type 2 diabetes
Type 2 Diabetes ICYMI
FDA panel starts review of rosiglitazone CV data
Type 2 Diabetes ICYMI
FDA panel supports easing rosiglitazone restrictions
Type 2 Diabetes ICYMI
FDA panels revisit rosiglitazone's cardiovascular safety
Type 2 Diabetes ICYMI
ACCORD: Insulin dose not implicated in excess CV deaths
Type 2 Diabetes ICYMI
Empagliflozin improves cardiovascular risk factors in T2DM
Type 2 Diabetes ICYMI
Twice daily regimen eases aspirin resistance in diabetes
Type 2 Diabetes ICYMI
Roche halts studies of experimental type 2 diabetes drug
Type 2 Diabetes ICYMI